Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2010
04/22/2010WO2009155439A3 Use of nitrated lipids for treatment of side effects of toxic medical therapies
04/22/2010WO2009155379A3 Artemisinin and derivatives thereof as antivirals
04/22/2010WO2009151770A3 Colchicine solid-state forms; methods of making; and methods of use thereof
04/22/2010WO2009151646A3 Non-invasive diagnostic agents and methods of diagnosing infectious disease
04/22/2010WO2009151644A3 Small molecule inhibitors of autotaxin methods of use
04/22/2010WO2009151561A3 Methods and compounds for antimicrobial intervention
04/22/2010WO2009146711A3 Method for purification of natural cobalamins by adsorption on insoluble materials containing carboxylic groups
04/22/2010WO2009143363A3 Functional metabolomics coupled microfluidic chemotaxis device and identification of novel cell mediators
04/22/2010WO2009138847A3 An improved process for the preparation of cefozopran
04/22/2010WO2009137660A3 Enhancement of drug therapy by mirna
04/22/2010WO2009129545A8 Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
04/22/2010WO2009129491A4 Beta adrenergic receptor agonists for treatment of pain and/or inflammation
04/22/2010WO2009128918A8 Combination therapy using a soluble hyaluronidase and a bisphosphonate
04/22/2010WO2009112022A3 Pharmaceutical composition for the diagnosis or treatment of diseases associated with zinc finger proteins
04/22/2010WO2009111787A3 ANTAGONISM OF PGF 2α RECEPTOR TO TREAT HYPERTENSION CHARACTERIZED BY ACTIVATION OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
04/22/2010WO2009107098A3 An oral treatment composition comprising potassium nitrate and hexylene glycol
04/22/2010WO2009103072A3 Erbb4 inhibitors and uses thereof in treatment of neuropsychiatric disorders
04/22/2010WO2009100438A3 Compounds that enhance atoh-1 expression
04/22/2010WO2009095773A3 Novel heterocycles
04/22/2010WO2009071804A3 Use of phytoecdysones in the preparation of a composition for acting on metabolic syndrome
04/22/2010WO2009068468A3 Pyridine compounds
04/22/2010WO2009048957A8 Antimalarial compounds with flexible side-chains
04/22/2010WO2009045370A3 Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
04/22/2010WO2009034558A3 Rhein or diacerein compositions
04/22/2010WO2009034546A3 Trans-decahydroisoquinoline derivatives
04/22/2010WO2009034346A8 Anti-bacterial agents
04/22/2010WO2009018186A3 Fly control method
04/22/2010WO2008142055A3 Antiviral agents
04/22/2010US20100100978 RNAi MEDIATED EXPRESSION INHIBITION OF A CHOLINERGIC PROTEIN
04/22/2010US20100100976 Methods and compositions related to apobec-1 expression
04/22/2010US20100100974 Models of Malignant Brain Cancer, and Therapeutic siRNAs Against Oncogenic Signaling Pathways, and Methods and Kits for Uses Therefor
04/22/2010US20100100030 Microbe Reductions with Photosensitizers
04/22/2010US20100099778 Device and method for producing therapeutic foam
04/22/2010US20100099776 Oily suspension of atovaquone
04/22/2010US20100099775 Method for ameliorating of post-anesthetic recovery
04/22/2010US20100099773 Inclusion complex of sibutramine and beta-cyclodextrin
04/22/2010US20100099772 Methods, compositions, and kits for treating pain and pruritis
04/22/2010US20100099771 Use of cooling agents to relieve mild ocular irritation and enhance comfort
04/22/2010US20100099770 Method for treating diabetic peripheral neuropathic pain
04/22/2010US20100099769 Benzylamine derivative or pharmaceutically acceptable acid addition salt thereof, and use thereof for medical purposes
04/22/2010US20100099768 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
04/22/2010US20100099767 Topical Pharmaceutical Formulation
04/22/2010US20100099766 Topical NSAID compositions having sensate component
04/22/2010US20100099765 Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
04/22/2010US20100099764 Production of arachidonic acid in oilseed plants
04/22/2010US20100099763 Triterpene compounds which are effective on improvement of brain function
04/22/2010US20100099762 Combination therapy
04/22/2010US20100099761 Levodopa Prodrug Mesylate Hydrate
04/22/2010US20100099760 Glycyrrhetinic Acid Derivatives
04/22/2010US20100099759 Agricultural applications of silver dihydrogen citrate
04/22/2010US20100099758 Regenerative wound healing using copper-silver citrate composition
04/22/2010US20100099757 Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders
04/22/2010US20100099756 Uses of incensole, incensole acetate and derivatives thereof
04/22/2010US20100099755 Chemotherapeutic flavonoids, and syntheses thereof
04/22/2010US20100099754 5,6-dimethyl xanthone-4-acetic acid derivatives and method of preparing the same
04/22/2010US20100099753 Dietary and pharmaceutical compositions containing tricyclic diterpenes and their derivates and their uses
04/22/2010US20100099752 Pharmaceutical composition containing bicyclic type compounds
04/22/2010US20100099751 Method of treating diabetes-related vascular complications
04/22/2010US20100099750 Chemically modified short interfering nucleic acid molecule for use in treatment of respiratory and pulmonary disease
04/22/2010US20100099749 Nucleic Acid Inhibitors Of Glutamate Receptors
04/22/2010US20100099748 used as modulators or targets of developmental processes or disorders associated with developmental dysfunctions, such as cancer; tumor suppressors genes
04/22/2010US20100099747 Reduction of polyalanine-induced protein aggregates and toxicity by ubiquilin
04/22/2010US20100099746 Novel nucleic acid
04/22/2010US20100099745 Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors
04/22/2010US20100099744 RNA INTERFERENCE MEDIATED INHIBITION OF MATRIX METALLOPROTEINASE 13 (MMP13) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
04/22/2010US20100099743 Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability
04/22/2010US20100099742 Sensitizing Cells for Apoptosis by Selectively Blocking Cytokines
04/22/2010US20100099741 Molecular Targets for Treatment of Learning and Memory Dysfunction
04/22/2010US20100099740 Methods and compositions for rnai mediated inhibition of gene expression in mammals
04/22/2010US20100099739 Compositions and Methods for Gene Silencing
04/22/2010US20100099738 Polyethylene glycol lipid conjugates and uses thereof
04/22/2010US20100099737 Compositions and methods for treating myelosuppression
04/22/2010US20100099736 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting mpt
04/22/2010US20100099735 Methods and compositions for improving cognitive function
04/22/2010US20100099734 Amino acid and its uses
04/22/2010US20100099733 Method for obtaining a stable dispersion of benzoyl peroxide
04/22/2010US20100099732 Medicaments useful as potassium channel modulators
04/22/2010US20100099731 Use of Endothelial Interrupters in the Treatment of Neurodegenerative Diseases
04/22/2010US20100099730 Annellated pyrrole compounds for cancer management
04/22/2010US20100099729 Nitric oxide donor compounds
04/22/2010US20100099728 Spiro-oxindole compounds and their use as therapeutic agents
04/22/2010US20100099727 Amino acid and peptide conjugates of arylalkylic acids for cosmetic use
04/22/2010US20100099726 Inhibitors of pyruvate kinase and methods of treating disease
04/22/2010US20100099725 Peroxisome proliferator activated receptor modulators
04/22/2010US20100099724 Formulations Comprising Triazoles and Alkoxylated Amines
04/22/2010US20100099723 Bioavailable compositions of metaxalone and processes for producing the same
04/22/2010US20100099722 2-(benzimidazol-1-yl)-n-(4-phenylthiazol-2-yl) acetamide derivatives
04/22/2010US20100099721 Novel compounds for the treatment of neurological disorders
04/22/2010US20100099720 Gene Polymorphisms as Sex-Specific Predictors in Cancer Therapy
04/22/2010US20100099719 Composition and method for treating proteinuria
04/22/2010US20100099718 Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
04/22/2010US20100099716 Cetp inhibitors
04/22/2010US20100099715 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2-receptor modulators
04/22/2010US20100099714 AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
04/22/2010US20100099713 2-aminopyridine derivatives as glucokinase activators
04/22/2010US20100099712 Substituted pyrazoline compounds with acat inhibition activity
04/22/2010US20100099711 Methods and Compositions Using Immunomodulatory Compounds for The Treatment and Management of Cancers and Other Diseases
04/22/2010US20100099710 Src family kinase inhibitors
04/22/2010US20100099709 Pyridin-2-yl-methylamine derivatives for treating opiate dependence
04/22/2010US20100099708 Piperidine Derivative Used for Treating Chemokine Receptor 5 Mediated Diseases